Why longevity needs cardiology's model for public messaging

Longevity medicine has reached an uncomfortable paradox: its scientific advances are more credible than ever, yet its public message is more fragmented. While senolytics, partial epigenetic reprogramming, and GLP-1 agents enter clinical trials, the consumer faces a landscape where two biological age tests return incomparable results, longevity clinics measure what suits them, and wearables report scores derived from secret algorithms with no shared scale. The field has named this the implementation gap, but its remedies target research infrastructure, not the layer where readers actually engage: a number on an app, a biomarker panel, a rejuvenation promise without context. Cardiology faced exactly this problem decades ago and did not create a new therapy—it created a communication instrument: Life's Essential 8, which distilled a contested risk landscape into eight components scored 0 to 100, later shown to track biological aging itself. Geroscience has assembled the material for its equivalent, even as experts disagree on fundamentals; panels have converged on which biomarkers matter in aging intervention trials and concluded that none suffices alone. What remains is translating that scientific consensus into an instrument ordinary people can actually use.